Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b

Journal of Viral Hepatitis

Volumn 20, Issue 3, 2013, Pages 167-173

  Toyota, J ^a   Ozeki, I ^a   Karino, Y ^a   Asahina, Y ^b   Izumi, N ^b   Takahashi, S ^c   Kawakami, Y ^c   Chayama, K ^c   Kamiya, N ^d   Aoki, K ^d   Yamada, I ^d   Suzuki, Y ^e   Suzuki, F ^e   Kumada, H ^e  

^a Sapporo Kosei General Hospital   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^e TORANOMON HOSPITAL   (Japan)

Author keywords

hepatitis C virus; monotherapy; subtype 1b; telaprevir

Indexed keywords

NONSTRUCTURAL PROTEIN 3; TELAPREVIR; VIRUS RNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EXPLORATORY RESEARCH; FEMALE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE; MALE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; THIRST; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VIREMIA; VIRUS LOAD; VIRUS STRAIN;

ADMINISTRATION, ORAL; AGED; ANTIVIRAL AGENTS; DRUG TOXICITY; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; JAPAN; MALE; MIDDLE AGED; MUTATION, MISSENSE; OLIGOPEPTIDES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PROTEINS;

EID: 84873454385     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01640.x     Document Type: Article

References (28)

1. World Health Organization. Fact sheet No.164 June 2011, Hepatitis C. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/index.html (accessed 27 June 2011).
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
3. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
4. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
5. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N,. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
6. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H,. Efficacy and safety of Telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: 134-142.
7. Chung H, Ueda T, Kudo M,. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
8. Okamoto H, Mishiro S,. Genetic heterogeneity of hepatitis C virus. Intervirology 1994; 37: 68-76.
9. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639.
10. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-1778.
11. Yamada I, Suzuki F, Kamiya N, et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat 2012; 19: e112-e119.
12. Manns MP, Wedemeyer H, Cornberg M,. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359.
13. Oze T, Hiramatsu N, Yakushijin T, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol 2011; 54: 604-611.
14. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751-759.
15. Suzuki F, Suzuki Y, Akuta N, et al. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. J Clin Virol 2010; 47: 76-78.
16. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
17. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
18. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
19. Sarrazin C, Zeuzem S,. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
20. Romano KP, Ali A, Royer WE, Schiffer CA,. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci USA 2010; 107: 20986-20991.
21. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280: 36784-36791.
22. 36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008; 52: 110-120.
23. Shimakami T, Welsch C, Yamane D, et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 2011; 140: 667-675.
24. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
25. Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011; 46: 929-937.
26. Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol 2011; 54: 872-878.
27. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748.
28. Anna SL, Daid FG, Eric L, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.